Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44ng Trends Data Analysis Biosimilars ernative Medicine Individualized Care Data Analysis Data Analysis 21 SUNDAY, SEPTEMBER 17, 2017 Data Analysis SUNDAY, SEPTEMBER 17, 2017 Data Analysis l Data Analysis l Data Analysis Symposium 4 Data Analysis Symposium 4 Data Analysis l 1:30 – 5:30 pm Next Wave in Cancer Medicine: Mechanisms & Progress for Emerging Therapeutics DISCOVERY TRACK CO-CHAIRS: Lucy Lee, PharmD, Director, Clinical Pharmacology, Infinity Pharmaceuticals Inc Luna Musib, PhD, Senior Scientist, Clinical Pharmacology, Genentech Research & Early Development (gRED) TARGET AUDIENCE: This Symposium will be useful for clinical pharmacologists, physicians, scientists and other allied professionals. GOALS AND OBJECTIVES: Following completion of this activity, the learner will be able to: 1. Provide an overview of cancer medicine in the past, present and into the future; 2. Present four selected cases of next-wave cancer medicine that are emerging treatments or novel targets in the drug pipeline; 3. Discuss the current landscape, clinical pharmacology, pharmacokinetics/pharmacodynamics, progress, therapeutic implications and challenges for the selected cases of next-wave cancer medicine. 1:30 – 2:00 pm Oncology Therapeutics: Snapshot of the Past, Present & Into the Future Lucy Lee, PharmD, Director, Clinical Pharmacology, Infinity Pharmaceuticals Inc 2:00 – 2:45 pm Antibody-Drug Conjugates Targeting Cancer Stem Cells Tae Han, PhD, Director, Clinical Pharmacology & Pharmacometrics, AbbVie Stemcentrx LLC 2:45 – 3:30 pm Personalized Cancer Vaccines Boosting Immunogenicity of Patient-specific Antigens Chi-Chung Li, PhD, Senior Scientist, Clinical Pharmacology, Genentech Research & Early Development (gRED) 3:30 – 4:00 pm / Break 4:00 – 4:40 pm Chimeric Antigen Receptor T-Cell Therapeutics for Cancer: Promise & Challenges Samuel Blackman, MD, PhD, Senior Vice President, Head of Clinical Development, Silverback Therapeutics Inc 4:40 – 5:20 pm Bispecific Antibodies Engaging Interaction of Both T-Cells & Tumor Cells Linzhong Li, PhD, Principal Scientist/Head, Biologics, Simcyp Ltd 5:20 – 5:30 pm Summary, Highlights and Q&A Luna Musib, PhD, Senior Scientist, Clinical Pharmacology, Genentech Research & Early Development (gRED) Symposia